Karyopharm Therapeutics Inc

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$99.7M
Website

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2020-04-21
Last Posted Date
2023-01-20
Lead Sponsor
Karyopharm Therapeutics Inc
Registration Number
NCT04355676

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-04-16
Last Posted Date
2023-01-20
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
190
Registration Number
NCT04349098
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

Lehigh Valley Hospital, Allentown, Pennsylvania, United States

and more 29 locations

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

First Posted Date
2020-02-05
Last Posted Date
2024-05-07
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
120
Registration Number
NCT04256707
Locations
🇮🇱

Soroka University Medical Center, Beer-Sheva, Israel

🇮🇱

Oncology Department Hillel Yaffe Medical Center, Hadera, Israel

🇮🇱

Rabin Medical Center, Petach Tikva, Israel

and more 8 locations

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-06-13
Last Posted Date
2024-06-11
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
263
Registration Number
NCT03555422
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇨🇦

London Health Sciences Centre (London Regional Cancer Centre), London, Ontario, Canada

🇺🇸

Oncology Associates of Oregon, Eugene, Oregon, United States

and more 74 locations

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

First Posted Date
2017-04-12
Last Posted Date
2024-08-21
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
402
Registration Number
NCT03110562
Locations
🇨🇦

Princess Margaret Cancer Research, Toronto, Ontario, Canada

🇺🇸

Kaiser Permanente Hawaii, Honolulu, Hawaii, United States

🇺🇸

Norton Cancer Institute, Louisville, Kentucky, United States

and more 153 locations

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2016-03-08
Last Posted Date
2024-11-25
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
60
Registration Number
NCT02702492
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

UCLA Health, Los Angeles, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

and more 5 locations

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

First Posted Date
2016-01-07
Last Posted Date
2024-07-24
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
277
Registration Number
NCT02649790
Locations
🇺🇸

University of Pennsylvania Abramson Cancer Center Clinical Research Unit, Philadelphia, Pennsylvania, United States

🇺🇸

(USO) Virginia Cancer Specialists, Fairfax, Virginia, United States

🇺🇸

Ohio State University, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

and more 43 locations

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

First Posted Date
2015-12-11
Last Posted Date
2023-01-26
Lead Sponsor
Karyopharm Therapeutics Inc
Registration Number
NCT02628704
Locations
🇺🇸

James R. Berenson MD, Inc, West Hollywood, California, United States

🇺🇸

Waverly Hematology, Cary, North Carolina, United States

Selinexor in Advanced Liposarcoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-11-17
Last Posted Date
2023-01-23
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
342
Registration Number
NCT02606461
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Sarcoma Oncology Center, Santa Monica, California, United States

🇺🇸

University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States

and more 68 locations

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2015-05-01
Last Posted Date
2023-01-26
Lead Sponsor
Karyopharm Therapeutics Inc
Registration Number
NCT02431351
© Copyright 2024. All Rights Reserved by MedPath